MC-02479

Synonym(s): MC 02479  |  RWJ 54428  |  MC-02,479

Class: Beta-lactam (cephalosporin)

Spectrum of activity:	Gram-positive
Details of activity:	Cephalosporin that has improved activity against strains producing β-lactamases. Against 112 strains of MRSA, MIC-90 was 2.0mcg/ml; inhibits cell wall synthesis; active against a broad spectrum of Gram positive bacteria including MRSA
Combined with other compounds:	Could be combined with aztreonam, fosfomycin, gentamicin or levofloxacin for empiric therapy
Description:	Chamberland S, Blais J, Hoang M, et al. In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria. Antimicrob Agents Chemother. 2001;45(5):1422-30.
Institute where first reported:	Johnson & Johnson Pharmaceutical R&D, USA; Essential Therapeutics [Ceased]
Year first mentioned:	1997
Highest developmental phase:	Phase 1
Development status:	Inactive
Reason Dropped:	This was to be developed as an anti-MRSA Cephalosporin [as its prodrug]. May have been dropped in favor of ceftobiprole which J&J were also developing at the same time (LS)

Chemical structure(s):
Canonical SMILES:	C1=C(C(=CN=C1)CSCCN)SC2=C(C(=O)O)N3C(=O)[C@H]([C@H]3SC2)NC(=O)/C(=N\O)/C4=C(Cl)SC(=N4)N
Isomeric SMILES:	C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)/C(=N\O)/C3=C(SC(=N3)N)Cl)C(=O)O)SC4=C(C=NC=C4)CSCCN
InChI:	InChI=1S/C20H20ClN7O5S4/c21-15-11(26-20(23)37-15)12(27-33)16(29)25-13-17(30)28-14(19(31)32)10(7-35-18(13)28)36-9-1-3-24-5-8(9)6-34-4-2-22/h1,3,5,13,18,33H,2,4,6-7,22H2,(H2,23,26)(H,25,29)(H,31,32)/b27-12-/t13-,18-/m1/s1
InChI Key:	LTUWUNMGTLOPNC-RLQAYIIJSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/9873517

External links:
Guide to Pharmacology:	MC-02479
Main Source:	https://www.jstage.jst.go.jp/article/antibiotics1968/53/11/53_11_1272/_pdf/-char/en
Citation:	https://journals.asm.org/doi/10.1128/aac.47.2.658-664.2003